Welcome to our dedicated page for Steris Plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris Plc stock.
News and updates about STERIS plc (NYSE: STE) focus on its role as a medical technology company that supports patient care with an emphasis on infection prevention. The company regularly issues press releases from Dublin, Ireland, describing its financial performance, dividends, leadership changes and investor events, giving readers insight into how its healthcare and life science products and services business is developing.
Investors following STERIS news can expect recurring coverage of quarterly and annual financial results, where the company reports total revenue from continuing operations, segment performance for Healthcare, Applied Sterilization Technologies (AST) and Life Sciences, and both GAAP and non-GAAP metrics such as adjusted earnings per diluted share and free cash flow. These releases often include management commentary and an outlook for future fiscal periods, along with detailed explanations of non-GAAP measures.
STERIS news also includes announcements of quarterly dividends, with information on dividend amounts, payment dates and record dates. Some releases highlight the company’s history of dividend growth. Governance and leadership developments, such as transitions in the Chief Financial Officer role or changes to the Board of Directors, are disclosed through both press releases and related SEC filings, and are frequently summarized in the news flow.
In addition, STERIS routinely announces conference calls to discuss financial results, providing access details and replay information for investors and analysts. Each release typically contains a cautionary statement regarding forward-looking information and references to risk factors described in the company’s SEC filings. Readers who monitor this news stream can follow how STERIS communicates its financial performance, strategic outlook, shareholder returns and governance matters over time.
STERIS plc (NYSE: STE) has successfully completed the acquisition of Cantel Medical, enhancing its offerings in infection prevention across several sectors, including endoscopy and dental. The acquisition is expected to create more value for customers and shareholders, according to CEO Walt Rosebrough. Financial advisors included Guggenheim Securities for STERIS and Centerview Partners for Cantel. This strategic move aims to bolster STERIS's product range and global reach in the healthcare market, aligning with its mission to promote a healthier world.
STERIS plc reported 4Q21 revenue of $873.5 million, a 6% increase year-over-year, contributing to a 3% full-year growth to $3.1 billion. Diluted earnings per share (EPS) for 4Q21 was $1.02, down from $1.43 in 4Q20, while adjusted EPS remained steady at $1.63. For fiscal 2022, STERIS anticipates revenue around $4.5 billion and adjusted EPS between $7.40 - $7.65. The company also declared a dividend of $0.40 per share.
STERIS plc (NYSE: STE) announced the retirement of David B. Lewis from its Board effective July 29, 2021, after serving since 2010. Paul E. Martin, former CIO at Baxter International, has been appointed as a new Board member as of May 5, 2021. The Board will return to nine members post-Annual Meeting. CEO Walt Rosebrough will also not stand for re-election, with COO Dan Carestio expected to be appointed as new CEO. These transitions aim to enhance Board effectiveness and bring in valuable insights from experienced leaders.
STERIS plc (NYSE: STE) announced a conference call scheduled for May 19, 2021, at 11:00 a.m. ET to discuss its fiscal 2021 fourth quarter and full-year financial results. A press release detailing these financial results will follow on May 18, 2021, after U.S. market close. The call can be accessed via www.steris-ir.com or by phone. This event highlights STERIS's commitment to transparency with investors regarding its financial performance and future outlook.
STERIS expects to finalize the acquisition of Cantel Medical by June 2, 2021, pending a shareholder vote on April 29, 2021. For fiscal 2021, the company reported a revenue increase of approximately 3%, totaling $3.1 billion, and an anticipated income from operations of about $548 million. Additionally, adjusted income is projected at $699 million, with free cash flow around $447 million. The effective tax rate is expected between 19-20%. Comprehensive results will be shared in an earnings call on May 19, 2021.
Cantel Medical Corp. (NYSE: CMD) reported its second quarter financial results for 2021, achieving net sales of $294.0M, up 1.9% year-over-year. Despite the pandemic's ongoing impact on elective procedures, GAAP earnings per diluted share rose to $0.27, compared to a loss of $(0.05) a year prior. Non-GAAP EPS increased by 29.5% to $0.79, driven by strong demand in dental and medical segments. The company has reduced its debt by $175.0M and ended the quarter with $243.1M in cash and gross debt of $988.4M, indicating solid financial health amidst challenges.
STERIS plc (NYSE: STE) announced the planned resignation of CEO Walt Rosebrough, effective July 29, 2021. Chief Operating Officer Dan Carestio will succeed him. Rosebrough will transition to a role as CEO Emeritus and Senior Advisor for two years. Under Rosebrough's leadership, STERIS achieved significant milestones, including tripling revenue and completing nearly 50 acquisitions, resulting in a market capitalization increase of over $14 billion. The Board expressed confidence in Carestio's leadership skills and successful integration of various business segments.
STERIS plc (NYSE: STE) announced a conference call to discuss its fiscal 2021 third quarter financial results on February 3, 2021, at 10:00 a.m. ET. Interested parties can join via phone or listen live online. A detailed press release will follow after market close on February 2, 2021. This call aims to provide insights into STERIS's financial performance and outlook. The company emphasizes its mission to create a healthier world through innovative healthcare solutions.
STERIS has announced its acquisition of Cantel Medical Corp for approximately $3.6 billion, valuing Cantel shares at $84.66. The deal includes expected synergies of $110 million by the fourth year and is aimed at enhancing STERIS's offerings in infection prevention, particularly in endoscopy and dental markets. The transaction is anticipated to close by the end of STERIS's first fiscal quarter of 2022, pending regulatory approvals. This acquisition positions STERIS strongly in a market focused on infection control, leveraging Cantel's existing infrastructure and customer base.
STERIS plc (NYSE: STE) will webcast presentations by CEO Walt Rosebrough at two upcoming investor conferences. The first is at 3:30 p.m. ET on January 11, 2021, during the Needham & Company Healthcare Conference, followed by the J.P. Morgan Healthcare Conference at 7:30 a.m. ET on January 13, 2021. The presentations will be accessible at steris-ir.com for thirty days. Furthermore, the company plans to announce its third-quarter fiscal 2021 results on February 2, followed by an investor call on February 3.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
